1 |
Priolo C, Tang D, Brahamandan M, et al. The isopeptidase USP2a protects human prostate cancer from apoptosis[J]. Cancer Res, 2006, 66(17): 8625-8632.
|
2 |
Tao BB, He H, Shi XH, et al. Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade[J]. J Clin Neurosci, 2013, 20(5): 717-720.
|
3 |
Kim J, Alavi Naini F, Sun Y, et al. Ubiquitin-specific peptidase 2a (USP2a) deubiquitinates and stabilizes β-catenin[J]. Am J Cancer Res, 2018, 8(9): 1823-1836.
|
4 |
Shi Y, Solomon LR, Pereda-Lopez A, et al. Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of aurora-A[J]. J Biol Chem, 2011, 286(45): 38960-38968.
|
5 |
Wei T, Biskup E, Gjerdrum LM, et al. Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma[J]. Oncotarget, 2016, 7(30): 48391-48400.
|
6 |
He X, Li Y, Li C, et al. USP2a negatively regulates IL-1β- and virus-induced NF-κB activation by deubiquitinating TRAF6[J]. J Mol Cell Biol, 2013, 5(1): 39-47.
|
7 |
Wang YY, Yang YX, Zhe H, et al. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties[J]. Drug Des Devel Ther, 2014, 8: 2075-2088.
|
8 |
Jing B, Liu M, Yang L, et al. Characterization of naturally occurring pentacyclic triterpenes as novel inhibitors of deubiquitinating protease USP7 with anticancer activity in vitro[J]. Acta Pharmacol Sin, 2018, 39(3): 492-498.
|
9 |
Wang Z, Xie W, Zhu M, et al. Development of a highly reliable assay for ubiquitin-specific protease 2 inhibitors[J]. Bioorg Med Chem Lett, 2017, 27(17): 4015-4018.
|
10 |
Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function[J]. J Comput Chem, 1998, 19(14): 1639-1662.
|
11 |
Renatus M, Parrado SG, D'Arcy A, et al. Structural basis of ubiquitin recognition by the deubiquitinating protease USP2[J]. Structure, 2006, 14(8): 1293-1302.
|
12 |
Qin D, Wang W, Lei H, et al. CDDO-Me reveals USP7 as a novel target in ovarian cancer cells[J]. Oncotarget, 2016, 7(47): 77096-77109.
|
13 |
He J, Lee HJ, Saha S, et al. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy[J]. Cell Death Dis, 2019, 10(4): 285.
|
14 |
Borella R, Forti L, Gibellini L, et al. Synthesis and anticancer activity of CDDO and CDDO-Me, two derivatives of natural triterpenoids[J]. Molecules, 2019, 24(22): 4097.
|
15 |
Medina MA, Oza G, Sharma A, et al. Triple-negative breast cancer: a review of conventional and advanced therapeutic strategies[J]. Int J Environ Res Public Health, 2020, 17(6): 2078.
|
16 |
Zhou L, Wang ZY, Yu SB, et al. CDDO-Me elicits anti-breast cancer activity by targeting LRP6 and FZD7 receptor complex[J]. J Pharmacol Exp Ther, 2020, 373(1): 149-159.
|
17 |
Shen H, Li L, Yang S, et al. Regulatory role of tumor necrosis factor receptor-associated factor 6 in breast cancer by activating the protein kinase B/glycogen synthase kinase 3β signaling pathway[J]. Mol Med Rep, 2017, 16(2): 2269-2273.
|
18 |
Kim EH, Deng C, Sporn MB, et al. CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice[J]. Cancer Prev Res (Phila), 2012, 5(1): 89-97.
|
19 |
Yu J, Qin B, Moyer AM, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine[J]. J Clin Invest, 2018, 128(6): 2376-2388.
|
20 |
Bishop RT, Marino S, Carrasco G, et al. Combined administration of a small-molecule inhibitor of TRAF6 and docetaxel reduces breast cancer skeletal metastasis and osteolysis[J]. Cancer Lett, 2020, 488: 27-39.
|
21 |
Wang Q, Ma S, Song N, et al. Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis[J]. J Clin Invest, 2016, 126(6): 2205-2220.
|
22 |
Gibellini L, Pinti M, Bartolomeo R, et al. Inhibition of Lon protease by triterpenoids alters mitochondria and is associated to cell death in human cancer cells[J]. Oncotarget, 2015, 6(28): 25466-25483.
|
23 |
Beinke C, Scherthan H, Port M, et al. Triterpenoid CDDO-Me induces ROS generation and up-regulates cellular levels of antioxidative enzymes without induction of DSBs in human peripheral blood mononuclear cells[J]. Radiat Environ Biophys, 2020, 59(3): 461-472.
|
24 |
El-Ashmawy M, Delgado O, Cardentey A, et al. CDDO-Me protects normal lung and breast epithelial cells but not cancer cells from radiation[J]. PLoS One, 2014, 9(12): e115600.
|